biotechnology

Oncocyte Reports Third Quarter 2023 Financial Results

Nov 9, 2023

-Launching First Products in 1H 2024- -Conference Call on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET- IRVINE, CA, November 09, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the third quarter of 2023, ended September 30, 2023. Third Quarter and Recent Highlights VitaGraft™ Kidney, the Company’s kidney transplant diagnostic test, received a positive coverage decision from CMS coverage; commercial revenue is...

Oncocyte to Announce Third Quarter 2023 Financial Results

Nov 3, 2023

Conference Call and Webcast on Thursday, November 9, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, November 3, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that the company will host a conference call and webcast on Thursday, November 9, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its third quarter financial results and recent highlights. The third quarter 2023 financial results press release will be issued the same day,...

10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis

Oct 24, 2023

NEW YORK, NY, October 24, 2023 - The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with several down by over 80-90% in recent years. This downturn has led to many biotech firms trading below their cash...

SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”

Oct 11, 2023

October 11, 2023 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has reported two significant milestones this week as it pursues development of its drug candidate, SLS009 for hematological malignancies. “SLS009 is a novel and highly selective CDK9 inhibitor which, to date, has shown tremendous therapeutic promise across multiple blood cancers.” Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS The company has dosed the first patient in a Phase Ib/II trial...

SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints

Sep 22, 2023

September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The data demonstrate meaningful anti-tumor activity and clinical responses as a monotherapy. Based on its...

Oncocyte’s VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier

Sep 18, 2023

Interventional study compares VitaGraft to current transplant rejection monitoring protocols Oncocyte’s VitaGraft assay detects antibody-mediated transplant rejection 10 months sooner than commonly used monitoring protocols (p<0.001) IRVINE, CA, September 18, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced the presentation of significant new clinical data at the European Society of Organ Transplant (ESOT) conference. The data was generated from a...

Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023

CEO Josh Riggs will be meeting with registered investors on September 11-12, 2023 IRVINE, CA, September 6, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it will participate in the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023, at the Lotte New York Palace Hotel. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 with registered investors during the conference. The Company’s virtual presentation...

Oncocyte’s VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage

Aug 28, 2023

First digital-droplet PCR assay to receive coverage Expect initial revenue generation in Q1 2024 IRVINE, CA, August 28, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that Palmetto GBA, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a positive coverage decision for the Company’s VitaGraft Kidney™ diagnostic test, confirming that the test has met the criteria for coverage under MolDX:...

Oncocyte Reports Second Quarter 2023 Financial Results

Aug 10, 2023

Conference Call on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 10, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today reported financial results for the second quarter of 2023, ended June 30, 2023. Second Quarter and Recent Highlights Transplant product launch on pace for Q4 early access. Manufacturing transfer process for 48-target universal assay began in June Expanding clinical utility for VitaGraft Kidney, a recent...

ONCOCYTE REGAINS COMPLIANCE WITH NASDAQ LISTING REQUIREMENTS

Aug 9, 2023

IRVINE, CA, August 9, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, today announced that it has received written notice from the Listing Qualifications Staff of the Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with the Nasdaq minimum bid price continued listing requirement and the matter is now closed. The Company was previously notified by Nasdaq on August 9, 2022 that it was not in compliance with the minimum bid price...

Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference

Aug 8, 2023

CEO Josh Riggs will be meeting with registered investors on Tuesday, August 15, 2023 IRVINE, CA, August 8, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will participate in the 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference taking place on August 14-15th, 2023. Josh Riggs, CEO of Oncocyte, will be meeting 1x1 or in small groups with registered investors on Tuesday, August 15, 2023. Interested investors can register for...

Oncocyte To Announce Second Quarter 2023 Financial Results

Aug 3, 2023

Conference Call and Webcast on Thursday, August 10, 2023, at 5:00 a.m. PT / 8:00 a.m. ET IRVINE, CA, August 3, 2023 - Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it will release its second quarter 2023 financial results on Thursday, August 10, 2023, prior to the U.S. market open. The company will host a conference call and webcast on Thursday, August 10, 2023, at 5:00 a.m. Pacific Time / 8:00 a.m. Eastern Time to discuss its financial results and...

NEWSROOM